UroGen Pharma Ltd. Ordinary Shares (URGN) Stock
Fundamentals
Source: third-party data provider, as of October 9, 2026
Compare with URGN
Recent news

Here's Why You Should Add URGN Stock to Your Portfolio Now
Here's Why You Should Add URGN Stock to Your Portfolio Now
URGN

Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in Focus
Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in Focus
URGN

Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 27.14%: Read This Before Placing a Bet
Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 27.14%: Read This Before Placing a Bet
URGN

Are You Looking for a Top Momentum Pick? Why Urogen Pharma (URGN) is a Great Choice
Are You Looking for a Top Momentum Pick? Why Urogen Pharma (URGN) is a Great Choice
URGN
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 30.30
- MACD 12/26/9
- -1.03
- EMA 9 of MACD
- -0.77
- MACD histogram
- -0.26
- SMA 50
- $43.79
- Price below SMA 50
- EMA 50
- $41.77
- Price below EMA 50
- SMA 200
- $30.28
- Price above SMA 200
- EMA 200
- $32.24
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 8, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 5 analysts
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.39 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Here's Why You Should Add URGN Stock to Your Portfolio Now
Here's Why You Should Add URGN Stock to Your Portfolio Now
URGN

Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in Focus
Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in Focus
URGN

Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 27.14%: Read This Before Placing a Bet
Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 27.14%: Read This Before Placing a Bet
URGN

Are You Looking for a Top Momentum Pick? Why Urogen Pharma (URGN) is a Great Choice
Are You Looking for a Top Momentum Pick? Why Urogen Pharma (URGN) is a Great Choice
URGN

Urogen Pharma Q2 Earnings Call Highlights
Urogen Pharma Q2 Earnings Call Highlights
URGN

Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates
Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates
URGN

Why Did CVS, URGN, CCK Stocks Hit 52-Week Highs Today?
Why Did CVS, URGN, CCK Stocks Hit 52-Week Highs Today?
URGN

UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run
UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run
URGN

Urogen Pharma (URGN) is a Great Momentum Stock: Should You Buy?
Urogen Pharma (URGN) is a Great Momentum Stock: Should You Buy?
URGN

Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Let Go of 10,000 Shares?
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Let Go of 10,000 Shares?
URGN
News tone: automated (AI) classification of the article's content, not a price prediction.
About UroGen Pharma Ltd. Ordinary Shares
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Ms. Elizabeth A. Barrett | President, CEO & Director | 1962 |
| Mr. Jason Drew Smith J.D. | General Counsel, Chief Compliance Officer & Corporate Secretary | 1972 |
| Dr. Mark P. Schoenberg M.D. | Chief Medical Officer | 1958 |
| Mr. Christopher Degnan CPA | Chief Financial Officer | 1980 |
| Mr. Vincent I. Perrone | Senior Director of Investor Relations | — |
| Ms. Alison Hardgrove | Senior Vice President of Human Resources | — |
| Dr. Marina Konorty Ph.D. | Executive Vice President of Research & Development and Technical Operations | — |
| Mr. James Ottinger R.ph. | Executive Vice President of Regulatory Affairs & Quality | — |
| Mr. Michael J. Louie M.D., M.P.H., M.Sc. | Chief Development Officer | — |
| Mr. Timothy Simon | Senior Vice President of Business Development & Portfolio Strategy | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 9, 2026
Technical indicators
- RSI 14
- 30.30
- MACD 12/26/9
- -1.03
- EMA 9 of MACD
- -0.77
- MACD histogram
- -0.26
- SMA 50
- $43.79
- Price below SMA 50
- EMA 50
- $41.77
- Price below EMA 50
- SMA 200
- $30.28
- Price above SMA 200
- EMA 200
- $32.24
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 8, 2026. Technical data, not a recommendation.
Analyst views
5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $42.00
- Average
- $57.00
- High
- $75.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +8.2 | -29.0 | -20.2 | |||||||||
| 2022 | -20.7 | -23.0 | +46.6 | -19.2 | -20.1 | +57.8 | -4.2 | +0.1 | +8.5 | +43.5 | -26.9 | +1.6 |
| 2023 | +20.3 | -6.4 | -12.8 | +18.9 | -30.7 | +5.9 | +114.2 | -13.9 | -22.8 | -18.1 | +16.1 | +15.1 |
| 2024 | +3.2 | +15.3 | -15.6 | -2.7 | -7.6 | +27.8 | -0.2 | -12.1 | -6.3 | -1.8 | +4.1 | -17.3 |
| 2025 | +2.9 | -15.6 | +19.3 | +9.5 | -62.8 | +183.1 | +46.4 | +0.3 | +2.2 | +14.9 | +39.7 | -17.7 |
| 2026 | -13.7 | +10.2 | -5.5 | +25.8 | +22.3 | +36.1 | +0.8 | +11.7 | -6.4 | -8.8 |



